NCT04723472

Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment

An Open Randomized Controlled Study of Bismuth Quadruple Therapy With Cefuroxime as Rescue Therapy for Helicobacter Pylori Infection

• Status: Suspended
• Phase: N/A
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: Shanghai East Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial treatment for Helicobacter pylori after initial or repeated treatment failure.

Detailed description

Introducing cefuroxime into the remedy treatment of Helicobacter pylori, on the one hand, the investigators will observe whether cefuroxime can replace tetracycline like amoxicillin, on the other hand, the investigators will observe whether it can reduce the rate of adverse effects caused by tetracycline and avoid the allergy of penicillin. If the experiment is successful, it will provide an effective and safe second-line treatment for the majority of patients with failed treatment of Helicobacter pylori.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Cefuroxime containing bismuth quadruple treatment	Cefuroxime containing bismuth quadruple treatment: Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days.
DRUG	Classic bismuth quadruple treatment	Classic bismuth quadruple treatment: Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days.

Timeline

• Start date: 2023-08-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2021-01-25
• Last updated: 2022-11-14

Locations

1 site across 1 country: China